Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK
Obesity is a risk factor for chronic kidney disease (CKD) and nonalcoholic fatty liver disease
(NAFLD). Recent studies identify mechanisms common to both diseases linked through an …
(NAFLD). Recent studies identify mechanisms common to both diseases linked through an …
Investigation and management of hypertriglyceridaemia
G Ferns, V Keti, B Griffin - Journal of clinical pathology, 2008 - jcp.bmj.com
While the precise definition of hypertriglyceridaemia remains contentious, the condition is
becoming more common in western populations as the prevalence of obesity and diabetes …
becoming more common in western populations as the prevalence of obesity and diabetes …
Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD)
R Lombardi, S Onali, D Thorburn… - Cochrane Database …, 2017 - cochranelibrary.com
Background Non‐alcohol related fatty liver disease (commonly called non‐alcoholic fatty
liver disease (NAFLD)) is liver steatosis in the absence of significant alcohol consumption …
liver disease (NAFLD)) is liver steatosis in the absence of significant alcohol consumption …
The effects of dietary weight loss with or without exercise training on liver enzymes in obese metabolic syndrome subjects
NE Straznicky, EA Lambert, MT Grima… - Diabetes, Obesity …, 2012 - Wiley Online Library
Aim: Insulin resistance and visceral adiposity are predisposing factors for fatty liver disease.
The main objectives of this study were (i) to compare the effects of caloric restriction (CR) …
The main objectives of this study were (i) to compare the effects of caloric restriction (CR) …
Lifestyle modifications for nonalcohol‐related fatty liver disease: a network meta‐analysis
E Buzzetti, A Linden, LMJ Best… - Cochrane Database …, 2021 - cochranelibrary.com
Background The prevalence of nonalcohol‐related fatty liver disease (NAFLD) varies
between 19% and 33% in different populations. NAFLD decreases life expectancy and …
between 19% and 33% in different populations. NAFLD decreases life expectancy and …
Weight reduction for non‐alcoholic fatty liver disease
L Peng, J Wang, F Li - Cochrane Database of Systematic …, 2011 - cochranelibrary.com
Background Non‐alcoholic fatty liver disease (NAFLD) is becoming a wide spread liver
disease. The present recommendations for treatment are not evidence‐based. Some of …
disease. The present recommendations for treatment are not evidence‐based. Some of …
Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis
O Komolafe, E Buzzetti, A Linden… - Cochrane Database …, 2021 - cochranelibrary.com
Background The prevalence of non‐alcohol‐related fatty liver disease (NAFLD) varies
between 19% and 33% in different populations. NAFLD decreases life expectancy and …
between 19% and 33% in different populations. NAFLD decreases life expectancy and …
Laparoscopic adjustable gastric banding in patients with unexpected cirrhosis: safety and outcomes
RM Woodford, PR Burton, PE O'Brien, C Laurie… - Obesity surgery, 2015 - Springer
Background The safety and efficacy of laparoscopic adjustable gastric banding (LAGB) in
the context of cirrhosis have not been established. We hypothesized that LAGB in cirrhotic …
the context of cirrhosis have not been established. We hypothesized that LAGB in cirrhotic …
Use of interleukin-22 in the treatment of fatty liver disease
YL Huang, ZH Huang, Q Sun - US Patent 10,786,551, 2020 - Google Patents
US10786551B2 - Use of interleukin-22 in the treatment of fatty liver disease - Google
Patents US10786551B2 - Use of interleukin-22 in the treatment of fatty liver disease …
Patents US10786551B2 - Use of interleukin-22 in the treatment of fatty liver disease …
Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis
D van der Poorten, J George - Clinics in liver disease, 2008 - Elsevier
Our mechanistic understanding of liver fibrosis has increased dramatically in recent years for
all liver diseases, and for hepatitis C and nonalcoholic steatohepatitis (NASH) in particular …
all liver diseases, and for hepatitis C and nonalcoholic steatohepatitis (NASH) in particular …